Contact
Prof. Dr. Jörg Steinbach
Executive Director (alternating)
Institute of Radiopharmaceutical Cancer Research
j.steinbach
hzdr.de
Phone: +49 351 260 3170, +49 351 260 3223
Fax: +49 351 260 13170
Prof. Dr. Michael Bachmann
Executive Director (alternating)
Radioimmunology
m.bachmannhzdr.de
Phone: +49 351 260 2060, +49 351 458 2101, +49 351 260 3170, +49 172 694 8424
Fax: +49 351 260 12060, +49 351 260 3232
Marita Kersten
Secretariat / Administration
Institute of Radiopharmaceutical Cancer Research
m.kerstenhzdr.de
Phone: +49 351 260 3223
Fax: +49 351 260 13223, +49 351 260 3232
Departments of Radiopharmaceutical Cancer Research
Radionuclide Theragnostics, Dr. Hans-Jürgen Pietzsch
- Molecular Metal Chelates
- Nanoscalic Systems
- Therapeutic Alpha-Emitters
- Preclinical Characterization of Radioconjugates
- Cyclotron-based Production of Radiometalnuclides
Radiopharmaceutical and Chemical Biology, Prof. Dr. Jens Pietzsch
- Radiotracer and Drug Development
- Theranostic Targets and Experimental Models
- Radiopharmacology and Cancer Imaging
- Tissue Regeneration and Inflammation Imaging
Positron Emission Tomography, Prof. Dr. Jörg van den Hoff
- Improved quantification of functional information in oncological PET
- Quantitative perfusion imaging using functional ASL-MRI
- Multimodal imaging and assessment of in-vivo quantification accuracy
- Motion compensation methods for PET
- High resolution PET image reconstruction
Neuroradiopharmaceuticals, Prof. Dr. Peter Brust
- Molecular imaging of adenosine signalling in cancer
- Molecular imaging of α7 nAChR in cancer and brain diseases
- [18F]Flubatine - a potential PET marker of early Alzheimer`s disease
- Development of new ligands and 18F-radiotracers for the vesicular acetylcholine transporter (VAChT) in brain
- New PET Radioligands for Imaging of Cannabinoid Receptors Type 2 (CB2) in the Human Brain
- Radioligands for PET Imaging of Cyclic Nucleotide Phosphodiesterases 2A, 5A and 10A
- Development of 18F-labelled PET radiotracers for the imaging of σ receptors in cancer and brain diseases
Radioimmunology, Prof. Dr. Michael Bachmann
- Antibody-based immunotherapeutics and diagnostics for therapy and imaging of tumors
- Cellular immunotherapeutics for an individualized immunotherapy and diagnostics
- Modulation of the tumor microenvironment via manipulation with regulatory T cells and checkpoint inhibitors
- Combination of immunotherapies with other tumor therapies (e.g. external or internal radiotherapy)
Radiopharmaceuticals Production, Dr. Frank Füchtner
- GMP-certified Radiopharmaceuticals Production
- Radiotracer and Radionuclides for Science
Contact
Prof. Dr. Jörg Steinbach
Executive Director (alternating)
Institute of Radiopharmaceutical Cancer Research
j.steinbachhzdr.de
Phone: +49 351 260 3170, +49 351 260 3223
Fax: +49 351 260 13170
Prof. Dr. Michael Bachmann
Executive Director (alternating)
Radioimmunology
m.bachmannhzdr.de
Phone: +49 351 260 2060, +49 351 458 2101, +49 351 260 3170, +49 172 694 8424
Fax: +49 351 260 12060, +49 351 260 3232
Marita Kersten
Secretariat / Administration
Institute of Radiopharmaceutical Cancer Research
m.kerstenhzdr.de
Phone: +49 351 260 3223
Fax: +49 351 260 13223, +49 351 260 3232
